S&P 500   3,655.07 (-0.20%)
DOW   29,731.31 (-0.31%)
QQQ   301.24 (-0.73%)
AAPL   121.00 (-1.40%)
MSFT   213.02 (-1.48%)
FB   281.86 (-1.64%)
GOOGL   1,790.00 (-0.30%)
AMZN   3,182.27 (-1.17%)
TSLA   548.28 (-6.24%)
NVDA   531.21 (-0.82%)
BABA   260.45 (-1.35%)
CGC   27.93 (+4.80%)
GE   10.17 (+0.20%)
MU   67.87 (+1.18%)
AMD   94.10 (+1.59%)
T   29.15 (+0.97%)
NIO   41.61 (-8.27%)
F   9.17 (-0.76%)
ACB   10.25 (+5.13%)
NFLX   495.71 (-1.76%)
BA   215.74 (+1.28%)
GILD   61.50 (+0.62%)
DIS   149.22 (-0.15%)
S&P 500   3,655.07 (-0.20%)
DOW   29,731.31 (-0.31%)
QQQ   301.24 (-0.73%)
AAPL   121.00 (-1.40%)
MSFT   213.02 (-1.48%)
FB   281.86 (-1.64%)
GOOGL   1,790.00 (-0.30%)
AMZN   3,182.27 (-1.17%)
TSLA   548.28 (-6.24%)
NVDA   531.21 (-0.82%)
BABA   260.45 (-1.35%)
CGC   27.93 (+4.80%)
GE   10.17 (+0.20%)
MU   67.87 (+1.18%)
AMD   94.10 (+1.59%)
T   29.15 (+0.97%)
NIO   41.61 (-8.27%)
F   9.17 (-0.76%)
ACB   10.25 (+5.13%)
NFLX   495.71 (-1.76%)
BA   215.74 (+1.28%)
GILD   61.50 (+0.62%)
DIS   149.22 (-0.15%)
S&P 500   3,655.07 (-0.20%)
DOW   29,731.31 (-0.31%)
QQQ   301.24 (-0.73%)
AAPL   121.00 (-1.40%)
MSFT   213.02 (-1.48%)
FB   281.86 (-1.64%)
GOOGL   1,790.00 (-0.30%)
AMZN   3,182.27 (-1.17%)
TSLA   548.28 (-6.24%)
NVDA   531.21 (-0.82%)
BABA   260.45 (-1.35%)
CGC   27.93 (+4.80%)
GE   10.17 (+0.20%)
MU   67.87 (+1.18%)
AMD   94.10 (+1.59%)
T   29.15 (+0.97%)
NIO   41.61 (-8.27%)
F   9.17 (-0.76%)
ACB   10.25 (+5.13%)
NFLX   495.71 (-1.76%)
BA   215.74 (+1.28%)
GILD   61.50 (+0.62%)
DIS   149.22 (-0.15%)
S&P 500   3,655.07 (-0.20%)
DOW   29,731.31 (-0.31%)
QQQ   301.24 (-0.73%)
AAPL   121.00 (-1.40%)
MSFT   213.02 (-1.48%)
FB   281.86 (-1.64%)
GOOGL   1,790.00 (-0.30%)
AMZN   3,182.27 (-1.17%)
TSLA   548.28 (-6.24%)
NVDA   531.21 (-0.82%)
BABA   260.45 (-1.35%)
CGC   27.93 (+4.80%)
GE   10.17 (+0.20%)
MU   67.87 (+1.18%)
AMD   94.10 (+1.59%)
T   29.15 (+0.97%)
NIO   41.61 (-8.27%)
F   9.17 (-0.76%)
ACB   10.25 (+5.13%)
NFLX   495.71 (-1.76%)
BA   215.74 (+1.28%)
GILD   61.50 (+0.62%)
DIS   149.22 (-0.15%)
Log in
NASDAQ:CBPO

China Biologic Products Stock Forecast, Price & News

$118.61
-0.38 (-0.32 %)
(As of 12/1/2020 12:00 AM ET)
Add
Compare
Today's Range
$118.35
Now: $118.61
$118.98
50-Day Range
$112.29
MA: $115.84
$118.99
52-Week Range
$97.91
Now: $118.61
$119.29
Volume84,773 shs
Average Volume113,543 shs
Market Capitalization$4.67 billion
P/E Ratio33.13
Dividend YieldN/A
Beta0.44
China Biologic Products Holdings, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. The company also provides human immunoglobulin and IVIG for original and secondary immunoglobulin deficiency, and immunoglobulin G secondary deficiency; human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; and human tetanus immunoglobulin for the prevention and therapy of tetanus. In addition, it offers placenta polypeptide for the treatment of cell immunity deficiency diseases, viral infection, and leucopenia, as well as assists in postoperative healing; factor VIII for treating coagulopathies; human fibrinogen; and human prothrombin complex concentrate for treating congenital and acquired clotting factor II, VII, IX, X deficiency, as well as excessive anticoagulant, vitamin K deficiency, etc. Further, the company is developing Human fibrinogen for the treatment for lack of fibrinogen and increase human fibrinogen concentration; and artificial dura and spinal dura mater products for use in brain and spinal surgeries. The company sells its products directly, as well as through distributors. The company was formerly known as China Biologic Products, Inc. and changed its name to China Biologic Products Holdings, Inc. in July 2017. China Biologic Products Holdings, Inc. is headquartered in Beijing, the People's Republic of China.
China Biologic Products logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.69 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CBPO
CUSIPN/A
Phone86-10-6598-3111
Employees2,269

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$503.70 million
Cash Flow$4.94 per share
Book Value$50.19 per share

Profitability

Net Income$138.81 million

Miscellaneous

Market Cap$4.67 billion
Next Earnings Date3/11/2021 (Estimated)
OptionableOptionable
$118.61
-0.38 (-0.32 %)
(As of 12/1/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CBPO News and Ratings via Email

Sign-up to receive the latest news and ratings for CBPO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











China Biologic Products (NASDAQ:CBPO) Frequently Asked Questions

How has China Biologic Products' stock price been impacted by COVID-19 (Coronavirus)?

China Biologic Products' stock was trading at $115.86 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CBPO stock has increased by 2.4% and is now trading at $118.61.
View which stocks have been most impacted by COVID-19
.

What stocks does MarketBeat like better than China Biologic Products?

Wall Street analysts have given China Biologic Products a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but China Biologic Products wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is China Biologic Products' next earnings date?

China Biologic Products is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for China Biologic Products
.

How were China Biologic Products' earnings last quarter?

China Biologic Products Holdings, Inc. (NASDAQ:CBPO) issued its quarterly earnings results on Monday, November, 23rd. The biopharmaceutical company reported $1.39 earnings per share for the quarter, beating the Zacks' consensus estimate of $1.28 by $0.11. The biopharmaceutical company earned $138.54 million during the quarter. China Biologic Products had a return on equity of 8.32% and a net margin of 27.43%. During the same quarter in the prior year, the business posted $1.40 earnings per share.
View China Biologic Products' earnings history
.

Are investors shorting China Biologic Products?

China Biologic Products saw a increase in short interest in October. As of October 30th, there was short interest totaling 583,100 shares, an increase of 25.5% from the October 15th total of 464,700 shares. Based on an average trading volume of 87,000 shares, the short-interest ratio is currently 6.7 days. Currently, 2.9% of the shares of the stock are sold short.
View China Biologic Products' Short Interest
.

Who are some of China Biologic Products' key competitors?

What other stocks do shareholders of China Biologic Products own?

Based on aggregate information from My MarketBeat watchlists, some companies that other China Biologic Products investors own include Lexicon Pharmaceuticals (LXRX), NVIDIA (NVDA), Gilead Sciences (GILD), Sarepta Therapeutics (SRPT), Micron Technology (MU), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA), ACADIA Pharmaceuticals (ACAD) and Amgen (AMGN).

Who are China Biologic Products' key executives?

China Biologic Products' management team includes the following people:
  • Mr. Joseph Chow, Chairman & CEO (Age 58)
  • Mr. Ming Yang, Chief Financial Officer (Age 48)
  • Mr. Ming Yin, Sr. VP (Age 42)

What is China Biologic Products' stock symbol?

China Biologic Products trades on the NASDAQ under the ticker symbol "CBPO."

Who are China Biologic Products' major shareholders?

China Biologic Products' stock is owned by a number of institutional and retail investors. Top institutional investors include Maso Capital Partners Ltd (2.24%), BlackRock Inc. (1.20%), Arrowstreet Capital Limited Partnership (0.27%), Ovata Capital Management Ltd (0.17%), State Street Corp (0.16%) and Nikko Asset Management Americas Inc. (0.15%).
View institutional ownership trends for China Biologic Products
.

Which institutional investors are selling China Biologic Products stock?

CBPO stock was sold by a variety of institutional investors in the last quarter, including Arrowstreet Capital Limited Partnership, Maso Capital Partners Ltd, JPMorgan Chase & Co., Nikko Asset Management Americas Inc., Voloridge Investment Management LLC, Point72 Asset Management L.P., Charles Schwab Investment Management Inc., and Handelsbanken Fonder AB.
View insider buying and selling activity for China Biologic Products
.

Which institutional investors are buying China Biologic Products stock?

CBPO stock was acquired by a variety of institutional investors in the last quarter, including Ovata Capital Management Ltd, BlackRock Inc., DekaBank Deutsche Girozentrale, Squarepoint Ops LLC, AQR Capital Management LLC, UBS Asset Management Americas Inc., State Street Corp, and Cubist Systematic Strategies LLC.
View insider buying and selling activity for China Biologic Products
.

How do I buy shares of China Biologic Products?

Shares of CBPO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is China Biologic Products' stock price today?

One share of CBPO stock can currently be purchased for approximately $118.61.

How big of a company is China Biologic Products?

China Biologic Products has a market capitalization of $4.67 billion and generates $503.70 million in revenue each year. The biopharmaceutical company earns $138.81 million in net income (profit) each year or $4.28 on an earnings per share basis. China Biologic Products employs 2,269 workers across the globe.

What is China Biologic Products' official website?

The official website for China Biologic Products is www.chinabiologic.com.

How can I contact China Biologic Products?

China Biologic Products' mailing address is 18TH FL JIALONG INTERNATIONALBUILDING 19 CHAOYANG PARK ROAD CHAOYANG DISTRICT, BEIJING F4, 100125. The biopharmaceutical company can be reached via phone at 86-10-6598-3111 or via email at [email protected]

This page was last updated on 12/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.